
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
PAT: A New Dawn for Drug Product Quality
over 17 years ago
Congress Approves Down Payment on Health Reformalmost 18 years ago
Inside IPEC: Regulation for Excipients is Brewing Across the Atlanticalmost 18 years ago
Quick Solutionsalmost 18 years ago
Pharma Capsulesalmost 18 years ago
The Rotation of Disinfectants Principle: True or False?almost 18 years ago
Going Green in Pharmaceuticalsalmost 18 years ago
Strategic Service Partnerships Gain Momentumalmost 18 years ago
In the Spotlight February 2009almost 18 years ago
Illuminating Heavy Metals Testing





